AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.110

-0.010-8.33%

Volume:26.52K

Turnover:2.95K

Market Cap:54.15M

PE:-3.31

High:0.120

Open:0.120

Low:0.110

Close:0.120

Loading ...

Overview Company News Filings

ASX Market Update: Rio Tinto & Glencore in merger talks | January 17, 2025

The Market Herald

BUZZ-Australia's Neurizon Therapeutics slides after FDA puts drug application on hold

BRIEF-Neurizon Therapeutics Says U.S. FDA Placed Co's Investigational New Drug Application Under Clinical Hold

Neurizon Therapeutics Says FDA Places its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low

MT Newswires Live

Neurizon Therapeutics - U.S. FDA Placed Co's Investigational New Drug Application for Nuz-001 Under Clinical Hold

THOMSON REUTERS

BRIEF-Neurizon Files Ind Application To Support Healey Als Platform Trial

Neurizon Files Ind Application to Support Healey ALS Platform Trial

THOMSON REUTERS

Neurizon Files Investigational New Drug Application with US FDA for Amyotrophic Lateral Sclerosis Trial; Shares Down 3%

MT Newswires Live

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Neurizon's ALS Drug Candidate Receives Orphan Medicinal Product Designation in Europe; Shares Down 3%

MT Newswires Live

BUZZ-Australia's Neurizon Therapeutics surges on getting OMPD for ALS drug in Europe

Neurizon Therapeutics Ltd-Neurizon Granted Ompd for Nuz-001 in Europe

THOMSON REUTERS

Neurizon Therapeutics Ltd-Neurizon Presents Company Update and 2025 Outlook

THOMSON REUTERS

Neurizon Therapeutics Ltd-Notice of Company Update Webinar

THOMSON REUTERS

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

BRIEF-Neurizon's NUZ-001 Reduces Aggregation Of Key ALS Disease Target TDP-43 In Preclinical Study

Neurizon's Nuz-001 Reduces Aggregation of Key ALS Disease Target Tdp-43 in Preclinical Study

THOMSON REUTERS

Neurizon Reports Positive Results from Preclinical Study of Amyotrophic Lateral Sclerosis Treatment Candidate; Shares fall 4%

MT Newswires Live

ASX Market Update: Utilities and Banks lead bourse higher | November 15, 2024

The Market Herald

BRIEF-Neurizon Therapeutics Gets EMA's Positive Opinion On Orphan Medicinal Product Designation For NUZ-001

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NUZ.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.11,"timestamp":1745302320000,"preClose":0.12,"halted":0,"volume":26517,"delay":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":492305766,"eps":-0.033278,"marketStatus":"Closed","change":-0.01,"latestTime":"04-22 16:12:00 AEST","open":0.12,"high":0.12,"low":0.11,"amount":2948,"amplitude":0.083333,"askPrice":0.12,"askSize":166133,"bidPrice":0.115,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":-0.033278,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.12,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.163707,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.46%","roe":"-150.50%","lyrEps":-0.020692,"volumeRatio":0.163707,"shares":492305766,"dividePrice":0,"high":0.12,"amplitude":0.083333,"preClose":0.12,"low":0.11,"week52Low":0.096,"pbRate":"4.55","psRate":"35.73","week52High":0.31,"institutionHeld":0,"latestPrice":0.11,"committee":-0.775561,"eps":-0.033278,"divideRate":0,"volume":26517,"delay":0,"ttmEps":-0.033278,"open":0.12,"prevYearClose":0.17,"prevWeekClose":0.12,"prevMonthClose":0.13,"prevQuarterClose":0.13,"fiveDayClose":0.105,"twentyDayClose":0.11,"sixtyDayClose":0.135},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2504970620","title":"ASX Market Update: Rio Tinto & Glencore in merger talks | January 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2504970620","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504970620?lang=en_us&edition=fundamental","pubTime":"2025-01-17 10:05","pubTimestamp":1737079500,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.21% at 8,345 points.The Discretionary sector has been the best performer, up 0.8%, followed closely by Utilities, up 0.75% and Industrials, up 0.7%.Rio Tinto Ltd has been down 0.6% as rumours of a merger with Glencore swirl. Talks are reported to be in the embryonic stages of development.Lynas Rare Earths has been down 3.7% after reporting a rise in sales revenues to $141.2 million and sales receipts to $145.9M during the second quarter of the 2025 fiscal year.Neurizon Therapeutics has been down 26.5% the US Food and Drug Administration has placed a clinical hold on its investigational new drug application for NUZ-001.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-rio-tinto-glencore-in-merger-talks-january-17-2025-2025-01-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NUZ.AU","RIO.AU","LYC.AU","BK7507","BK7511","BK7095","BK7096"],"gpt_icon":0},{"id":"2504197697","title":"BUZZ-Australia's Neurizon Therapeutics slides after FDA puts drug application on hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2504197697","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504197697?lang=en_us&edition=fundamental","pubTime":"2025-01-17 09:31","pubTimestamp":1737077511,"startTime":"0","endTime":"0","summary":"** Shares of Neurizon Therapeutics    fall 26.5% to A$0.125, their lowest level since Jan. 15, 2024   ** Stock falls as much as 29.4% in its biggest intraday pct drop since early September 2020   ** Biotech firm receives notification from the U.S. FDA that its investigational new drug  application for NUZ-001 to treat amyotrophic lateral sclerosis , a neurodegenerative disease, has been put under clinical hold    ** IND application is a request for authorisation to administer experimental drugs to humans   ** Co says FDA has outlined certain concerns over sufficiency of information to assess application   ** More than 2.9 mln shares change hands, 7.1 times the 30-day avg   ** Neurizon down 26.5% YTD, including current session's moves ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096","BK4139","LENZ"],"gpt_icon":0},{"id":"2504976503","title":"BRIEF-Neurizon Therapeutics Says U.S. FDA Placed Co's Investigational New Drug Application Under Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2504976503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504976503?lang=en_us&edition=fundamental","pubTime":"2025-01-17 09:26","pubTimestamp":1737077188,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Says U.S. FDA Placed Co's Investigational New Drug Application Under Clinical HoldJan 17  - Neurizon Therapeutics Ltd NUZ.AX:U.S. FDA PLACED CO'S INVESTIGATIONAL NEW DRUG APPLICATION FOR NUZ-001 UNDER CLINICAL HOLDFurther company coverage: NUZ.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nFWN3OC123:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2504757389","title":"Neurizon Therapeutics Says FDA Places its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2504757389","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504757389?lang=en_us&edition=fundamental","pubTime":"2025-01-17 09:18","pubTimestamp":1737076710,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics'  investigational new drug application for NUZ-001 was placed under clinical hold by the US Food and Drug Administration amid concerns about the sufficiency of information to assess the application, potential risks to human subjects, and the proposed dosing regime, according to a Friday filing with the Australian bourse.The company is developing NUZ-001 as a potential treatment for amyotrophic lateral sclerosis, a motor neuron disease.The US FDA is expected to provide detailed feedback within 30 days, providing necessary clarifications to progress the application, the filing said.Shares fell past 26% in midday trade Friday and earlier hit a new 52-week low.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","LENZ","BK4139","BK7096"],"gpt_icon":0},{"id":"2504892126","title":"Neurizon Therapeutics - U.S. FDA Placed Co's Investigational New Drug Application for Nuz-001 Under Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2504892126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504892126?lang=en_us&edition=fundamental","pubTime":"2025-01-17 07:00","pubTimestamp":1737068407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC123:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2492900989","title":"BRIEF-Neurizon Files Ind Application To Support Healey Als Platform Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900989","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492900989?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:38","pubTimestamp":1734525486,"startTime":"0","endTime":"0","summary":"Dec 18 (Reuters) - Neurizon Therapeutics Ltd   :   * NEURIZON FILES IND APPLICATION TO SUPPORT HEALEY ALS PLATFORM TRIALSource text:    Further company coverage:","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2492073519","title":"Neurizon Files Ind Application to Support Healey ALS Platform Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492073519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492073519?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:11","pubTimestamp":1734523913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NI185:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2492992546","title":"Neurizon Files Investigational New Drug Application with US FDA for Amyotrophic Lateral Sclerosis Trial; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492992546","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492992546?lang=en_us&edition=fundamental","pubTime":"2024-12-18 12:24","pubTimestamp":1734495867,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  submitted an investigational new drug application with the US Food and Drug Administration to conduct a phase 2/3 trial of its drug candidate, NUZ-001, for amyotrophic lateral sclerosis, according to a Wednesday filing with the Australian bourse.Once approved, the Healey ALS Platform study will start patient enrollment in the first half of next year, the filing said.Amyotrophic lateral sclerosis is a motor neuron disease characterized by the progressive degeneration of nerve cells in the spinal cord and brain, the Johns Hopkins Medicine website showed.The company's shares were down 3% in recent Wednesday trade.Price : $0.17, Change: $-0.01, Percent Change: -2.86%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","LU1043141123.HKD","LU0426417589.USD","LU0994945656.USD","LU0426412945.USD","LU2238339852.HKD","NUZ.AU","LU0345774631.USD","BK7096","AUD"],"gpt_icon":0},{"id":"2492405339","title":"Neurizon Files IND Application to Support HEALEY ALS Platform Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492405339","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492405339?lang=en_us&edition=fundamental","pubTime":"2024-12-18 10:59","pubTimestamp":1734490740,"startTime":"0","endTime":"0","summary":"IND application submission to the U.S. Food and Drug Administration  is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001. The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies, and manufacturing information for NUZ-001. The FDA has a period of 30 days to review the IND application. MELBOURNE, Australia, Dec. 18, 2024 /PRNewswire/ -- , a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce the filing of an Investigational New Drug  application to the U.S. Food and Drug Administration  for its lead candidate, NUZ-001. This milestone is a pivotal step in enabling the commencement of a Phase 2/3 clinical trial within the HEALEY ALS Platform Trial framework. The FDA has a period of 30 days to review the IND application.The IND is the mechanism by which the sponsor provides critical information to the FDA to obtain authorization to initiate th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5j5dXN8qUYnlhVgNPlMKYg--~B/aD0xMTM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5j5dXN8qUYnlhVgNPlMKYg--~B/aD0xMTM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/neurizon-files-ind-application-support-025900106.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurizon-files-ind-application-support-025900106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NUZ.AU","MGH.AU","BK7095","IND.AU","BK7055","BK7096"],"gpt_icon":0},{"id":"2492942924","title":"Neurizon's ALS Drug Candidate Receives Orphan Medicinal Product Designation in Europe; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492942924","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492942924?lang=en_us&edition=fundamental","pubTime":"2024-12-18 10:41","pubTimestamp":1734489667,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics'  lead amyotrophic lateral sclerosis  drug candidate, NUZ-001, received orphan medicinal product designation from the European Medicines Agency, according to a Tuesday filing with the Australian bourse.The designation offers benefits like reduced regulatory fees, free protocol assistance, and 10 years of market exclusivity in the European Union upon product approval, the filing said.The company plans to expedite preparations for the phase 2/3 Healey ALS platform trial to facilitate the clinical validation of NUZ-001, according to the filing.Neurizon Therapeutics' shares fell nearly 3% in afternoon trade Wednesday.Price : $0.17, Change: $-0.01, Percent Change: -2.86%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","LU2238339852.HKD","LU0994945656.USD","LU0426412945.USD","LU1043141123.HKD","BK7096","LU0345774631.USD","LU0426417589.USD","AUD","BK4125"],"gpt_icon":0},{"id":"2492560549","title":"BUZZ-Australia's Neurizon Therapeutics surges on getting OMPD for ALS drug in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2492560549","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492560549?lang=en_us&edition=fundamental","pubTime":"2024-12-17 11:30","pubTimestamp":1734406238,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics surges on getting OMPD for ALS drug in Europe** Shares of biotech firm Neurizon Therapeutics NUZ.AX rise 9.1% to A$0.18, set for their biggest one-day pct gain since early June** European Medicines Agency  grants orphan medicinal product designation  to co's NUZ-001 drug aimed at treating amyotrophic lateral sclerosis , a terminal neurodegenerative disease** EMA gives orphan product designation to facilitate medicine development for rare diseases affecting not more than 5 in 10,000 people in the EU** Co says orphan designation provides a framework of incentives including reduced regulatory fees, free protocol assistance and 10-year market exclusivity** Stock up 56.5% YTD, including session's moves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4N3NI07A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2492362582","title":"Neurizon Therapeutics Ltd-Neurizon Granted Ompd for Nuz-001 in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2492362582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492362582?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:52","pubTimestamp":1734385976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUE5FHDLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2490682319","title":"Neurizon Therapeutics Ltd-Neurizon Presents Company Update and 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2490682319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490682319?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:08","pubTimestamp":1733976504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUE4D5RDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2489412656","title":"Neurizon Therapeutics Ltd-Notice of Company Update Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2489412656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489412656?lang=en_us&edition=fundamental","pubTime":"2024-12-05 06:29","pubTimestamp":1733351357,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUEBDPVXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2484943438","title":"Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484943438","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484943438?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:30","pubTimestamp":1732019400,"startTime":"0","endTime":"0","summary":"Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis . Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43  by ~50% and ~55% respectively, in M337V Motor Neurons in response to a stressor. Provides valuable insights into the mechanism of action of NUZ-001 in ALS and strengthens promising efficacy results from the Phase 1 MEND study completed earlier this year in patients with ALS. Two separate preclinical studies were conducted in collaboration with Ncardia, a leading human induced pluripotent stem cell  technology company. The firststudy evaluated the ability of NUZ-001 and its major active metabolite  to reduce TDP-43 aggregation in M337V Motor Neurons co-cultured with astrocytes in response to a stressor. TAR DNA-binding protein 43  is a known driver of ALS pathology. The results show NUZ-001 and NUZ-001 Sulfone significantly and dos","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5j5dXN8qUYnlhVgNPlMKYg--~B/aD0xMTM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5j5dXN8qUYnlhVgNPlMKYg--~B/aD0xMTM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/neurizons-nuz-001-reduces-aggregation-123000423.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurizons-nuz-001-reduces-aggregation-123000423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2484376919","title":"BRIEF-Neurizon's NUZ-001 Reduces Aggregation Of Key ALS Disease Target TDP-43 In Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484376919","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484376919?lang=en_us&edition=fundamental","pubTime":"2024-11-19 18:41","pubTimestamp":1732012918,"startTime":"0","endTime":"0","summary":"Nov 19 (Reuters) - Neurizon Therapeutics Ltd   :   * NEURIZON'S NUZ-001 REDUCES AGGREGATION OF KEY ALS DISEASE TARGET TDP-43 IN PRECLINICAL STUDYSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2484299960","title":"Neurizon's Nuz-001 Reduces Aggregation of Key ALS Disease Target Tdp-43 in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484299960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484299960?lang=en_us&edition=fundamental","pubTime":"2024-11-19 15:18","pubTimestamp":1732000719,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA3PRC7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2484313691","title":"Neurizon Reports Positive Results from Preclinical Study of Amyotrophic Lateral Sclerosis Treatment Candidate; Shares fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484313691","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484313691?lang=en_us&edition=fundamental","pubTime":"2024-11-18 12:34","pubTimestamp":1731904468,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics (ASX:NUZ) reported positive results from a preclinical study of its lead drug candidate, NUZ-001, for Amyotrophic Lateral Sclerosis (ALS), according to a Friday filing with the A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","LU0426417589.USD","LU0345774631.USD","BK4125","LU1043141123.HKD","AUD","LU0994945656.USD","LU2238339852.HKD","LU0426412945.USD","NUZ.AU"],"gpt_icon":0},{"id":"2483109360","title":"ASX Market Update: Utilities and Banks lead bourse higher | November 15, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483109360","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483109360?lang=en_us&edition=fundamental","pubTime":"2024-11-15 10:30","pubTimestamp":1731637800,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.35% at 8,255 points in afternoon trade.All four big banks are higher today and Westpac and ANZ are leading the charge, both up 1%.Utilities are the best performing sector, up 2.7%, followed by Telecommunication and Industrials, up 1.1%.Health Care is the one and only sector in the red today, down 2%.Mineral Resources  has been down 4.2% on news companies connected to CEO Chris Ellison’s daughter were asked to repay $158,000. The request followed an investigation into a rent relief arrangement that lasted eleven years.Neurizon Therapeutics has been up 5.2% on preclinical study results for its lead drug candidate in treating amyotrophic lateral sclerosis.Stavely Minerals has been down 7.4% after kicking off diamond drilling at its high-grade Junction Copper-Silver Discovery at its Copper-Gold Project in Western Victoria.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-utilities-and-banks-lead-bourse-higher-november-15-2024-2024-11-15/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","NUZ.AU","BK7507","SVY.AU","MIN.AU","BK7095","BK7504"],"gpt_icon":0},{"id":"2482558278","title":"BRIEF-Neurizon Therapeutics Gets EMA's Positive Opinion On Orphan Medicinal Product Designation For NUZ-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2482558278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482558278?lang=en_us&edition=fundamental","pubTime":"2024-11-11 15:16","pubTimestamp":1731309410,"startTime":"0","endTime":"0","summary":"Nov 11 (Reuters) - Neurizon Therapeutics Ltd   :   * NEURIZON THERAPEUTICS RECEIVES POSITIVE OPINION ON ORPHAN MEDICINAL PRODUCT DESIGNATION FOR NUZ-001 IN EUROPESource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[]}}